KalVista Pharmaceuticals, Inc. (KALV) Research and Development Expense USD 2014 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
KalVista Pharmaceuticals, Inc. quarterly/annual Research and Development Expense history and growth rate from 2014 to 2023.
  • KalVista Pharmaceuticals, Inc. Research and Development Expense for the quarter ending January 31, 2024 was $22.5 M, a 12.3% increase year-over-year.
  • KalVista Pharmaceuticals, Inc. Research and Development Expense for the twelve months ending January 31, 2024 was $84.9 M, a 12.4% increase year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Research and Development Expense for 2022 was $80.3 M, a 14.4% increase from 2021.
  • KalVista Pharmaceuticals, Inc. annual Research and Development Expense for 2021 was $70.2 M, a 70% increase from 2020.
  • KalVista Pharmaceuticals, Inc. annual Research and Development Expense for 2020 was $41.3 M, a 2.72% increase from 2019.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $84.9 M $22.5 M +$2.46 M +12.3% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-11
Q3 2023 $82.4 M $19.1 M +$1.01 M +5.6% Aug 1, 2023 Oct 31, 2023 10-Q 2023-12-07
Q2 2023 $81.4 M $19.3 M +$1.12 M +6.16% May 1, 2023 Jul 31, 2023 10-Q 2023-09-07
Q1 2023 $80.3 M $24 M +$4.74 M +24.6% Feb 1, 2023 Apr 30, 2023 10-K 2023-07-10
Q4 2022 $75.5 M $20.1 M +$325 K +1.65% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-11
Q3 2022 $75.2 M $18.1 M +$531 K +3.03% Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-07
Q2 2022 $74.7 M $18.2 M +$4.52 M +33% May 1, 2022 Jul 31, 2022 10-Q 2023-09-07
Q1 2022 $70.2 M $19.2 M +$7.34 M +61.8% Feb 1, 2022 Apr 30, 2022 10-K 2023-07-10
Q4 2021 $62.8 M $19.7 M +$10.6 M +117% Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-09
Q3 2021 $52.2 M $17.5 M +$8.4 M +91.8% Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-08
Q2 2021 $43.8 M $13.7 M +$2.5 M +22.4% May 1, 2021 Jul 31, 2021 10-Q 2022-09-08
Q1 2021 $41.3 M $11.9 M +$2.39 M +25.2% Feb 1, 2021 Apr 30, 2021 10-K 2023-07-10
Q4 2020 $38.9 M $9.1 M -$2.14 M -19% Nov 1, 2020 Jan 31, 2021 10-Q 2022-03-10
Q3 2020 $41 M $9.15 M -$641 K -6.55% Aug 1, 2020 Oct 31, 2020 10-Q 2021-12-09
Q2 2020 $41.7 M $11.2 M +$1.48 M +15.3% May 1, 2020 Jul 31, 2020 10-Q 2021-09-09
Q1 2020 $40.2 M $9.49 M -$1.65 M -14.8% Feb 1, 2020 Apr 30, 2020 10-K 2022-07-07
Q4 2019 $41.8 M $11.2 M +$3.58 M +46.8% Nov 1, 2019 Jan 31, 2020 10-Q 2021-03-11
Q3 2019 $38.3 M $9.79 M +$1.91 M +24.3% Aug 1, 2019 Oct 31, 2019 10-Q 2020-12-10
Q2 2019 $36.4 M $9.69 M +$1.33 M +15.9% May 1, 2019 Jul 31, 2019 10-Q 2020-09-14
Q1 2019 $35 M $11.1 M +$5.29 M +90.3% Feb 1, 2019 Apr 30, 2019 10-K 2021-07-13
Q4 2018 $29.7 M $7.65 M +$3.1 M +68.2% Nov 1, 2018 Jan 31, 2019 10-Q 2020-03-10
Q3 2018 $26.6 M $7.88 M +$3.52 M +80.6% Aug 1, 2018 Oct 31, 2018 10-Q 2019-12-03
Q2 2018 $23.1 M $8.36 M +$4.88 M +140% May 1, 2018 Jul 31, 2018 10-Q 2019-09-09
Q1 2018 $18.2 M $5.85 M -$2.2 M -27.3% Feb 1, 2018 Apr 30, 2018 10-K 2020-07-01
Q4 2017 $20.4 M $4.55 M +$1.21 M +36.2% Nov 1, 2017 Jan 31, 2018 10-Q 2019-03-14
Q3 2017 $19.2 M $4.36 M +$4.03 M +1214% Aug 1, 2017 Oct 31, 2017 10-Q 2018-12-14
Q2 2017 $15.2 M $3.48 M +$2.53 M +267% May 1, 2017 Jul 31, 2017 10-Q 2018-09-14
Q1 2017 $12.7 M $8.05 M +$4.52 M +128% Feb 1, 2017 Apr 30, 2017 10-K 2019-07-16
Q4 2016 $8.15 M $3.34 M -$283 K -7.81% Nov 1, 2016 Jan 31, 2017 10-Q 2018-03-16
Q3 2016 $8.43 M $332 K -$3.2 M -90.6% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-08
Q2 2016 $11.6 M $947 K -$3.56 M -79% Apr 1, 2016 Jun 30, 2016 10-Q 2016-08-12
Q1 2016 $15.2 M $3.53 M -$370 K -9.48% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-12
Q4 2015 $15.6 M $3.62 M +$591 K +19.5% Nov 1, 2015 Jan 31, 2016 10-Q 2017-03-16
Q3 2015 $15 M $3.53 M +$1.45 M +69.2% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $13.5 M $4.5 M +$2.75 M +157% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 $10.8 M $3.9 M +$2.48 M +174% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q4 2014 $8.29 M $3.03 M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-30
Q3 2014 $2.09 M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 $1.75 M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 $1.43 M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.